Table 1.
Primary cutaneous lymphoproliferative disorders (PCLDs) developed following COVID-19 vaccination reported in the literature
| Study | Month, year | Country | Diagnosis | n | Age (years) and sex (M/F) | Vaccine |
|---|---|---|---|---|---|---|
| New onset condition | ||||||
| Català A | January, 2022 | Spain | Cutaneous B lymphoma | 1 | Unknown | Unknown |
| Bresler SC | November, 2022 | USA | Primary cutaneous CD8+ peripheral T-cell lymphoma | 1 | 62 F | Pfizer-BioNTech |
| Avallone G | November, 2022 | Italy | CD4+ PCSMLPD | 2 | 52 F 45 M |
Pfizer-BioNTech |
| Avallone G | November, 2022 | Italy | Sézary syndrome | 1 | 80 F | Pfizer-BioNTech |
| Hooper MJ | July, 2022 | USA | LyP type A | 2 | 50 M 20 F |
Pfizer-BioNTech |
| Avallone G | November, 2022 | Italy | LyP type A | 2 | 60 M 61 F |
Pfize-BioNTech |
| Koumaki D | July, 2022 | Greece | LyP type D | 2 | 60 F 66 F |
1 AstraZeneca 1 Pfizer-BioNTech |
| Bresler SC | November, 2022 | USA | Lymphomatoid reaction vs. LyP | 1 | 53 M | Moderna |
| Avallone G | November, 2022 | Italy | Atypical PLEVA | 1 | 62 F | AstraZeneca and Pfizer-BioNTech |
| Hooper MJ | July, 2022 | USA | PLEVA | 2 | 50 F “late teens” M | Pfizer-BioNTech |
| Avallone G | November, 2022 | Italy | CPL | 2 | 55 M 55 M |
Pfizer-BioNTech |
| Mintoff D | January, 2022 | Malta | CPL | 1 | 68 F | Pfizer-BioNTech |
| Hooper MJ | July, 2022 | USA | CPL | 2 | 70 F 50 M |
Pfizer-BioNTech |
| Verdaguer J | 2023 | Spain | CPL | 1 | 51 F | Pfizer-BioNTech |
| Recurrence/reactivation of latent pre-existing disease | ||||||
| Brumfiel CM | April, 2021 | USA | Primary cutaneous anaplastic large-cell lymphoma | 1 | 79 M | Pfizer-BioNTech |
| Avallone G | November, 2022 | Italy | CD4+PCSMLPD | 1 | 49 M | Pfizer-BioNTech |
| Avallone G | November, 2022 | Italy | Sézary syndrome | 2 | 58 M 61 M |
Pfizer-BioNTech |
| Panou E | February, 2022 | Greece | Large-cell transformation of a folliculotropic MF | 1 | 60 M | AstraZeneca |
| Avallone G | November, 2022 | Italy | Erythrodermic MF | 1 | 61 M | Pfizer-BioNTech |
| Panou E | February, 2022 | Greece | LyP type A | 1 | 73 F | AstraZeneca |
| Avallone G | November, 2022 | Italy | LyP type A | 1 | 67 M | Pfizer-BioNTech |
| Avallone G | November, 2022 | Italy | CPL | 1 | 47 F | Pfizer-BioNTech |
LyP: Lymphomatoid papulosis; PLEVA: Pityriasis lichenoides et varioliformis acuta; CD4+ PCSMLPD: Primary cutaneous CD4+small/medium T-cell lymphoproliferative disorder; CPL: Cutaneous pseudolymphoma; MF: Mycosis fungoides